Frequently Asked Questions
The global DNA probe-based diagnostics market was valued at USD 14.2 Billion in 2022.
The DNA probe-based diagnostics market is expected to grow at a CAGR of 5.10% between 2023 and 2030, reaching USD 20.11 Billion in 2030.
Infectious diseases is the leading segment by applications, holding over 43% share in value in 2022.
The cancer segment governs the demand for DNA probe-based diagnostics worldwide, holding a massive share of over 80% in 2022.
The genetic predisposition segment will post the highest CAGR during the forecast period.
Asia Pacific is fueling the growth of the DNA probe-based diagnostics industry, with an over one-third share in 2022.
The top players include Abbott Molecular, Beckman Coulter Inc. Becton, Dickinson and Company, bioMerieux, F. Hoffmann-La Roche Ltd., GE Healthcare Life Sciences, Luminex Corporation, QIAGEN N.V., Siemens Healthineers, and Thermo Fischer Scientific Inc.
DNA probe-based diagnostic innovation is still driven by ongoing research and development in genomics and molecular diagnostics.
Some healthcare providers need help implementing DNA probe-based diagnostics on a broad scale due to the high cost of the tests and the requirement for skilled personnel to perform and interpret them, major market restraints.
With the huge growth potential in the Asia Pacific, Infectious disease prevalence continues to be a significant healthcare concern are the major opportunities in the DNA probe-based diagnostics industry.